Adaptimmune Therapeutics PLC (ADAP) Deferred Tax Assets, Valuation Allowance USD 2014 - 2023

Historical data

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary: Adaptimmune Therapeutics PLC quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from 2014 to 2023.
Adaptimmune Therapeutics PLC Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $295 M, a 83.7% increase year-over-year.

Deferred Tax Assets, Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date	Report	Filed
Q4 2023	$295 M	+$134 M	+83.7%	Dec 31, 2023	10-K	2024-03-06
Q4 2022	$161 M	+$28.1 M	+21.2%	Dec 31, 2022	10-K	2024-03-06
Q4 2021	$132 M	+$50 M	+60.7%	Dec 31, 2021	10-K	2024-03-06
Q4 2020	$82.4 M	+$23.2 M	+39.3%	Dec 31, 2020	10-K	2023-03-06
Q4 2019	$59.2 M	+$18.4 M	+45.1%	Dec 31, 2019	10-K	2021-02-25
Q4 2018	$40.8 M	+$13.3 M	+48.6%	Dec 31, 2018	10-K	2020-02-27
Q4 2017	$27.4 M	+$9.82 M	+55.8%	Dec 31, 2017	10-K	2019-02-27
Q4 2016	$17.6 M	+$8.18 M	+86.8%	Dec 31, 2016	10-K	2018-03-15
Q4 2015	$9.43 M			Dec 31, 2015	10-K	2017-03-13
Q2 2015	$8.32 M	+$4.01 M	+93%	Jun 30, 2015	10-K	2017-03-13
Q2 2014	$4.31 M			Jun 30, 2014	8-K	2016-07-08

* An asterisk sign (*) next to the value indicates that the value is likely invalid.